CytomX Therapeutics SG&A Expense (Quarterly) Analysis

CytomX Therapeutics Inc (CTMX)

1.61 0.00 (0.00%) USD | NASDAQ | Apr 30, 14:04

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2014. Upgrade now.

Date	Value
December 31, 2023	7.827M
September 30, 2023	6.813M
June 30, 2023	7.401M
March 31, 2023	7.977M
December 31, 2022	10.07M
September 30, 2022	10.49M
June 30, 2022	11.75M
March 31, 2022	10.54M
December 31, 2021	9.456M
September 30, 2021	11.08M
June 30, 2021	9.393M
March 31, 2021	9.227M
December 31, 2020	9.145M
September 30, 2020	8.634M
June 30, 2020	8.68M
March 31, 2020	9.572M
December 31, 2019	9.217M
September 30, 2019	8.463M
June 30, 2019	9.411M

Date	Value
March 31, 2019	9.674M
December 31, 2018	8.975M
September 30, 2018	8.137M
June 30, 2018	9.042M
March 31, 2018	7.356M
December 31, 2017	7.616M
September 30, 2017	6.249M
June 30, 2017	6.049M
March 31, 2017	5.691M
December 31, 2016	5.154M
September 30, 2016	5.033M
June 30, 2016	4.647M
March 31, 2016	5.04M
December 31, 2015	4.009M
September 30, 2015	4.051M
June 30, 2015	2.552M
March 31, 2015	1.946M
December 31, 2014	2.181M
September 30, 2014	1.463M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

6.813M

Minimum

Sep 2023

11.75M

Maximum

Jun 2022

9.218M

Average

9.227M

Median

Mar 2021

SG&A Expense (Quarterly) Benchmarks